Andrew P Wolfe, Age 48Howard Beach, NY

6865668, Mar 8, 2005

Sep 30, 1998

09/787168

Martin Bene{hacek over (s)} - Berkely CA, US
Steven M. Nowick - New York NY, US
Andrew Wolfe - Los Gatos CA, US

Trustees of Columbia University in the City of New York - New York NY

G06F007/00
H03M007/40

712300, 712208, 341 65, 341 67

There is disclosed a decoder circuit () for decoding input data coded using a variable length coding technique, such as Huffman coding. The decoder circuit () comprises an input buffer (), a logic circuit () coupled to the input buffer (), and an output buffer () coupled to the logic circuit (). The logic circuit () includes a plurality of computational logic stages for decoding the input data, the plurality of computational logic stages arranged in one or more computational threads. At least one of the computational threads is arranged as a self-timed ring, wherein each computational logic stage in the ring produces a completion signal indicating either completion or non-completion of the computational logic of the associated computational logic stage. Each completion signal is coupled to a previous computational logic stage in the ring. The previous computational logic stage performs control operations when the completion signal indicates completion and performs evaluation of its inputs when the completion signal indicates non-completion.

2013006, Mar 14, 2013

Feb 28, 2011

13/581032

Hans-Guido Wendel - New York NY, US
Andrew L. Wolfe - New York NY, US
Konstantinos John Mavrakis - New York NY, US
Elisa Oricchio - New York NY, US
Adolfo A. Ferrando - New York NY, US
Kim De Keersmaecker - Leuven, BE
Teresa Palomero - New York NY, US
Franki Speleman - Ghent, BE
Pieter Van Vlierberghe - Ghent, BE

A61K 31/7088
A61P 35/00
C07H 21/02
A61K 39/395
C12Q 1/68
C12N 5/09

4241301, 435 613, 435 612, 435375, 536 245, 514 44 A

The present invention relates to microRNAs (miRNAs) which are associated with cancer, particularly including hematologic malignancies, and particularly T-cell acute lymphoblastic leukemia (T-ALL), and to the assessment and modulation thereof in the treatment and management of cancer. The present invention is directed to methods and compositions for diagnosing and treating cancer, particularly T-ALL, by modulating miRNAs, and the use of miRNAs and antagonists thereof, particularly antagomirs, for predicting and assessing response to treatment, in assays for isolating and selecting antagists, and as compositions for the treatment and management of cancer. Methods and compositions are provided for treatment or alleviation of cancer, particularly T-ALL, with antagonists/antagomirs of miRNAs, particularly one or more of miR-19b, miR-20a, miR26, miR92, miR148 and miR223.

2015021, Aug 6, 2015

Apr 22, 2015

14/693832

- New York NY, US
Andrew Wolfe - New York NY, US
Kamini Sing - New York NY, US
Yi Zhong - New York NY, US
Phillip Drewe - New York NY, US

MEMORIAL SLOAN KETTERING CANCER CENTER - New York NY

G01N 33/50
G01N 33/574
A61K 31/429
A61K 31/357
A61K 31/58

Methods are provided for identifying agents capable of modulating cap-dependent RNA translation by comparing translation efficiency in the presence and absence of the agent in an in-vitro or in-vivo translation system that comprises eIF4A and an mRNA having one or more eIF4A-dependent translation-controlling motifs. The modulation of translation in the presence of the agent indicates the agent as capable of modulating cap-dependent mRNA translation. The method can be used to identify anti-cancer agents and oncogenes that may be responsible for tumorigenesis.